ASSEMBLY BIOSCIENCES INC (ASMB)
Health Care · biotechnology · NASDAQ
Assembly Biosciences is a clinical-stage biotech developing small-molecule therapies to treat chronic viral and liver diseases, supported by a strategic partnership with Gilead Sciences.
What ASSEMBLY BIOSCIENCES INC does
Assembly Biosciences is a clinical-stage biotechnology company focused on developing small-molecule therapeutics for serious viral and liver diseases. Its pipeline includes investigational therapies for hepatitis delta virus (HDV), chronic liver diseases (PBC and PSC), hepatitis B virus (HBV), and transplant-related herpesviruses, alongside a portfolio of long-acting helicase-primase inhibitors for recurrent genital herpes that have been licensed to Gilead Sciences.
Recent developments
In 2026, the company expanded its lead program candidate, ABI-6250, into primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) in addition to HDV. It also completed a $115 million gross financing transaction to fund ongoing Phase 2 preparations for its liver programs.
From ASSEMBLY BIOSCIENCES INC's filing of 2026-08-13.
Themes: virology, hepatitis B (HBV), hepatitis delta virus (HDV), liver disease, herpesvirus therapeutics, drug discovery / development
Fundamentals
- Price$22.82 as of 2026-10-08 close
- Market cap$465M as of 2026-08-07 (share count; price 2026-10-08)
- 1-year return-10.5% 2025-10-08 close $25.50 → 2026-10-08 close $22.82
- P/En/a negative earnings
- Net margin-8.5% FY2025, SEC XBRL
- ROE-3.0% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Revenue growth (YoY)+121.1% as of 2026-09-03
- Beta1.02 as of 2026-09-03
- Last reported earnings2026-05-07 SEC EDGAR Form 8-K (Item 2.02)
How ASMB compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ASSEMBLY BIOSCIENCES INC looks technically
ASSEMBLY BIOSCIENCES INC (ASMB) is trading 19.4% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 21 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 45, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 31, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 3 trading days ago. It is 4.7% above its 52-week low (its lowest price of the past year).
Trend
8
| Distance from the 200-day | it is trading 19.4% below its 200-day average, the long-term trend line — a long-term downtrend | -19.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $28.64 | $28.64 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $28.31 | $28.31 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 36 calendar days ago — the swings before that are what the structure reading is measured on | 36 sessions |
| Wave structure | its recent swings can be read as a completed five-part upward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes above 37.01. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible five-wave upward sequence, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 21 trading days ago — a "golden cross", a bullish long-term signal | 21 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 45, with sellers in control | 45.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 31, neither overbought (above 70) nor oversold (below 30) | 31.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($21.80 to $25.89) — its "stochastic" reading is 25 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 24.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 22 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $39.70 | $39.70 |
|---|---|---|
| From the 52-week high | it is 42.5% below its 52-week high (its highest price of the past year) | -42.5% |
| Above the 52-week low | it is 4.7% above its 52-week low (its lowest price of the past year) | +4.7% |
| Below the 52-week high | it is 42.5% below its highest point of the past year | 42.5% |
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $811.57 (set on 2018-03-13) | $811.57 |
| Given back of the 52-week move | over the past year its closes ranged ($22.18 to $38.50), and it has recovered only a small part of its fall from last year’s high — 4% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $32.27 to $32.79. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 3.9% |
| From the all-time high | it is 97.2% below its all-time high | -97.2% |
| Nearest price level | it is trading 7.8% below a resistance level at $24.59 — a price it turned at twice since 2026-01-30, most recently on 2026-07-29. Since 2024-10-08 it has 5 such levels below the current price and 10 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +7.8% |
| All-time low | its lowest closing price on record is $7.72 (set on 2023-11-22) | $7.72 |
| Above the all-time low | it is 195.5% above its all-time low | +195.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 68th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.30 between its high and its low — about 5.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.30 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $20.52 and $28.45 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $20.52 – $24.48 – $28.45 |
| Typical daily range (% of price) | its price moves about 5.7% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.7% |
| Stretch from the 200-day average | it is trading 4.2 daily ranges below its 200-day average price (19.4% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.2 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.84× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
3
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bullish engulfing | 1 session ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 1 session ago |
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.7% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.7% |
|---|---|---|
| Gap filled | a 2.1% gap up opened on 2026-09-17 has been "filled" 15 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 15 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 36.4 percentage points (the stock lost 35.3% while the market gained 1.0%) | -36.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 24.4 percentage points (the stock lost 20.6% while the market gained 3.8%) | -24.4% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 39.4 percentage points (the stock lost 21.9% while the market gained 17.5%) | -39.4% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 25.5 percentage points (the stock lost 10.5% while the market gained 15.0%) | -25.5% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 25% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 10.3% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -25.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 19% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $28.03 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | -18.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 21% below the average price paid since it last reported on 2026-08-13 (its 10-Q), so the typical buyer over that stretch is under water. That average is $28.96 — a volume-weighted average of daily closes over 40 sessions, not a true tick-by-tick VWAP. | -21.2% |
Price levels it has turned at before
ASMB last closed at $22.82 on 2026-10-08. Since 2024-10-08 it has turned at 5 prices below its last close and 10 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $24.59 | Resistance | 7.8% above the last close | turned there twice · 2026-01-30 to 2026-07-29 |
| $25.90 | Resistance | 13.5% above the last close | turned there three times · 2026-01-21 to 2026-05-21 |
| $26.47 | Resistance | 16.0% above the last close | turned there twice · 2026-03-30 to 2026-04-21 |
| $18.02 | Support | 21.0% below the last close | turned there twice · 2024-11-04 to 2025-01-03 |
| $17.48 | Support | 23.4% below the last close | turned there twice · 2024-12-02 to 2025-07-22 |
| $16.82 | Support | 26.3% below the last close | turned there twice · 2024-12-19 to 2025-08-01 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $37.01.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 21 trading days, since 2026-09-10.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Pulled back from the 12-month high · Broke down to a new 20-day low · lagging the market · Printed a doji candle | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$52.00 range $43.00 – $62.00
Analyst estimates, as of 2026-10-05. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ASMB
- Consensus EPS estimate-$0.4947 next reporting period, as of 2026-10-05
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["High dependency on the collaboration with Gilead Sciences for the development and commercialization of its HPI program.","Clinical development is inherently uncertain, and product candidates may fail to demonstrate safety or efficacy in future trials.","The company has a history of operating losses and will require significant additional capital to fund its research and development programs."]
What changed in the latest 10-Q
AI-assisted comparison of ASMB's 10-Q filed 2026-08-13 against the prior one filed 2026-05-07.
Management's Discussion & Analysis (MD&A)
The two filings could not be meaningfully compared for this section.
Risk Factors
- Added:
- Newer filing states 6250 is for treatment of (a) chronic hepatitis delta virus (HDV) infection and (b) primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), both cholestatic liver diseases (CLD), whereas older filing described 6250 only as an orally bioavailable hepatitis delta virus (HDV) entry inhibitor.
- Newer filing describes Gilead as controlling the clinical development of 5366 and 1179, with initiation of a Phase 2 study of 1179 expected by the end of 2026, and states Gilead does not intend to develop 5366 further at this time.
- Newer filing states the company received Gilead's clinical development plan and budget for the HPI program in June 2026.
- Newer filing states Gilead is considering possible evaluation of 1179 as part of a combination strategy with HIV pre-exposure prophylaxis (PrEP).
- Newer filing states the company's decision regarding the Profit-Share will be made after receipt and review of Gilead's commercial costs estimates, which will complete the opt-in package.
- Newer filing states for 6250 HDV, preparation for a Phase 2 study is on-going, with initiation expected in the fourth quarter of 2026.
- Newer filing states the company announced expansion of 6250 into PBC and PSC, with preparation for a Phase 2 study on-going and initiation expected in the first quarter of 2027.
- Newer filing states the company conducted a pre-IND meeting with the FDA to discuss planned development of 6250 in CLD, and the official minutes support advancement of the CLD program.
- Newer filing states the company completed a $115.0 million gross financing transaction expected to extend funding beyond planned Phase 2 studies of 6250 in both HDV and CLD.
- Newer filing describes 4334 process to identify potential partners as continuing, and states the company does not plan to advance 4334 further without a partner.
- Removed:
- Older filing stated 2025 was a pivotal year with data readouts reported for 5366, 1179, 6250 and 4334, and that 7272 was nominated and advanced into regulatory-enabling studies.
- Older filing stated all participants in the Phase 1a/b studies of 5366 and 1179 have completed dosing and follow up, reinforcing continued confidence in safety and efficacy findings previously disclosed.
- Older filing stated for 6250, all participants in the Phase 1a study have completed dosing and follow up, and chronic toxicology studies have been completed establishing support for anticipated Phase 2 doses.
- Older filing described 1179 as in-licensed to the company as part of the collaboration with Gilead.
- Older filing stated development of 5366 and 1179 would be in Gilead's sole control following completion of the Phase 1a/b studies, which the company was managing until complete.
- Older filing stated the company reported interim data from the Phase 1b portion of the 5366 study in August 2025, including a 94% reduction in HSV-2 shedding rate compared to placebo (p<0.01) over the 29-day evaluation period.
- Reworded:
- Newer filing describes the company's focus as 'serious viral and liver diseases' while older filing described it as 'serious viral diseases'.
- Newer filing identifies product candidates as GS-5366 and GS-1179, and states they have been exclusively licensed to Gilead Sciences, Inc.; older filing identified them as ABI-5366 and ABI-1179 without stating exclusive license to Gilead in that sentence.
- Newer filing describes 6250 as an 'orally bioavailable sodium taurocholate co-transporting peptide (NTCP) inhibitor' whereas older filing described it as an 'orally bioavailable hepatitis delta virus (HDV) entry inhibitor'.
- Newer filing describes additional research programs against 'multiple viral and liver disease targets' whereas older filing stated 'multiple antiviral targets'.
- Newer filing introduces 'Profit-Share' as a defined term in the HPI/Gilead discussion; older filing did not use this term.
- Newer filing states Gilead does not intend to develop 5366 further at this time; older filing contained no equivalent statement.
- Newer filing refers to the company's ongoing progression of product candidates in the second quarter of 2026, whereas older filing referenced progression in 2026 generally.
- Older filing referred to the FDA as 'U.S. Food and Drug Administration's (FDA) Good Laboratory Practice (GLP) toxicology studies' while newer filing text available does not show the full equivalent closing sentence about 5366's nonclinical profile.
- Notes:
- The newer filing text ends mid-sentence ('To reach that goal, we discovered and began the clinical development of a novel, potent, long-acting HPI for recurrent genital herpes, 5366, which demonstrated low nanomolar potency in vitro against both HSV-1 and HSV-2 clinical isolates and a favorable nonclinical safety profile in the FDA's Good Laboratory Practice (GLP) toxicology studies. In additio') and the older filing text also ends mid-sentence ('We reported interim data from the Phase 1b portion of the 5366 study in August 2025...'), so the comparison is limited to the text provided and may omit trailing content differences.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 180 days · read to 2026-10-040 buys · 1 sell ($674) — 1 selling insider
Most recent open-market transaction: 2026-06-17. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ASMB's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding ASMB as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 1,207,183
- Reported value $33,173,389
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about ASMB's institutional holders → See what each manager we track holds →
Short interest (FINRA)
ASMB had 2,095,568 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
ASMB had 10.3% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.26 days to cover at the same settlement.
- Reported short interest (shares) 2,095,568
- Short interest (% of shares outstanding) 10.3%
- Prior settlement (shares) 2,120,055
- Reported change -1.16%
- Days to cover (reported) 6.26
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Gilead Sciences (GILD)
- Vir Biotechnology (VIR)
- Alnylam Pharmaceuticals (ALNY)
- Arrowhead Pharmaceuticals (ARWR)
- GlaxoSmithKline (GSK)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ASMB vs…
Frequently asked questions
What does ASSEMBLY BIOSCIENCES INC (ASMB) do?
Assembly Biosciences is a clinical-stage biotechnology company focused on developing small-molecule therapeutics for serious viral and liver diseases. Its pipeline includes investigational therapies for hepatitis delta virus (HDV), chronic liver diseases (PBC and PSC), hepatitis B virus (HBV), and transplant-related herpesviruses, alongside a portfolio of long-acting helicase-primase inhibitors for recurrent genital herpes that have been licensed to Gilead Sciences.
What sector is ASSEMBLY BIOSCIENCES INC (ASMB) in?
ASSEMBLY BIOSCIENCES INC (ASMB) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are ASSEMBLY BIOSCIENCES INC's (ASMB) competitors?
Notable peers of ASSEMBLY BIOSCIENCES INC (ASMB) include Gilead Sciences, Vir Biotechnology, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals and GlaxoSmithKline. This peer set is informational only — not financial advice.
Is ASSEMBLY BIOSCIENCES INC (ASMB) overbought or oversold right now?
ASSEMBLY BIOSCIENCES INC (ASMB) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 31, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ASMB come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.